Mizuho Securities Issues a Buy Rating on Arcus Biosciences (RCUS)

In a report released today, Mara Goldstein from Mizuho Securities assigned a Buy rating to Arcus Biosciences (RCUSResearch Report), with a price target of $51.00. The company’s shares closed last Thursday at $31.98.

According to, Goldstein is a 4-star analyst with an average return of 4.6% and a 37.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $62.80.

See Insiders’ Hot Stocks on TipRanks >>

Arcus Biosciences’ market cap is currently $2.26B and has a P/E ratio of 75.22.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Read More on RCUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More